TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30397906

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation (ICHV)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normoventilation
Number of subjects: 25
Study: 28986051

Group type: EXPERIMENTAL
Intervention: Intravenous 0.2 mg/kg dexamethasone (group D)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (group P)
Number of subjects: 80
Study: 25896330

Group type: EXPERIMENTAL
Intervention: HEPA filtration
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo filtration
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Indoor PM2.5 exposure in traffic-impacted locations
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Indoor PM2.5 exposure in woodsmoke-impacted locations
Number of subjects: 83
Study: 25060792

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich olive oil (366 mg/kg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Polyphenol-poor olive oil (2.7 mg/kg)
Number of subjects: 47
Study: 22000326

Group type: EXPERIMENTAL
Intervention: Two-session adolescent-only intervention (BI-A)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Two-session adolescent and additional parent session (BI-AP)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Assessment-only control condition (CON)
Number of subjects: 315
Study: 19415056

Group type: EXPERIMENTAL
Intervention: Lysine Clonixinate
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dipyrone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study: 17717452

Group type: EXPERIMENTAL
Intervention: Coloplasty (CP-1)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Straight Anastomosis (SA)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Colonic J-Pouch (JP)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Coloplasty (CP-2)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) scores
Number of subjects: 364
Study: 14768624

Group type: EXPERIMENTAL
Intervention: VIP light (400-3400 nm, 95% polarization, 40 mW cm(‐2), 12 J cm(‐2))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VInP light (400-3400 nm, no polarization, 38 mW cm(‐2), 11.2 J cm(‐2))
Number of subjects: 0
Study: 11270012

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl administered 15 min before surgery (group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural fentanyl administered 15 min before waking at the end of the operation (group II)
Number of subjects: 40
Study: 9509205

Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg.kg‐1
Number of subjects: 52

Group type: COMPARATOR
Intervention: Thiopentone 1.0 mg.kg‐1
Number of subjects: 52
Study: 7830998

Group type: EXPERIMENTAL
Intervention: Vitreon as an intraoperative hydrokinetic retinal manipulator
Number of subjects: 234

Group type: COMPARATOR
Intervention: C3F8, SF6, silicone oil as postoperative tamponading agents
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Vitreon as a short-term tamponade
Number of subjects: 234
Study: 2905250

Group type: EXPERIMENTAL
Intervention: Roxatidine acetate 150 mg daily at 9 pm for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30121609

Group type: EXPERIMENTAL
Intervention: Triple pill (fixed low-dose combination of three antihypertensive drugs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 26801948

Group type: EXPERIMENTAL
Intervention: 3:1 C:V method
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 9:3 C:V method
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 15:2 C:V method
Number of subjects: 84

Group type: COMPARATOR
Intervention: CCaV-120 method
Number of subjects: 84
Study: 26253237

Group type: EXPERIMENTAL
Intervention: Supported self-management intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both arms (supported self-management and standard treatment)
Number of subjects: 80
Study: 24240932

Group type: EXPERIMENTAL
Intervention: Weight management
Number of subjects: 150

Group type: COMPARATOR
Intervention: General lifestyle advice (Control)
Number of subjects: 150
Study: 21174051

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BOTOX®, Allergan Inc.) + standard care
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo + standard care
Number of subjects: 300
Study: 18281242

Group type: EXPERIMENTAL
Intervention: Pre-ovulatory pertubation with low-dose lignocaine
Number of subjects: 130

Group type: COMPARATOR
Intervention: No pertubation
Number of subjects: 130
Study: 16532491

Group type: EXPERIMENTAL
Intervention: Glycoprotein (GP) IIb/IIIa inhibitors
Number of subjects: 81
Study: 12649057

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral smoking cessation treatment plus moderate-intensity physical activity
Number of subjects: 217

Group type: COMPARATOR
Intervention: Cognitive-behavioral smoking cessation treatment plus contact control
Number of subjects: 217
Study: 11573317

Group type: EXPERIMENTAL
Intervention: Sting-Aid (aluminum sulfate solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adolph's meat tenderizer dissolved in water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fresh water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (seawater)
Number of subjects: 0
Study: 9692778

Group type: EXPERIMENTAL
Intervention: BQ‐123 (15 microg min(‐1) for 60 min and subsequently 60 microg min(‐1) for 60 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ET‐1 (2.5 ng kg(‐1) min(‐1) for 120 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BQ‐123 co-infused with ET-1
Number of subjects: 10
Study: 8139627

Group type: EXPERIMENTAL
Intervention: Epoetin beta (250 IU/kg subcutaneously three times a week from day 3 to day 42)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control (no epoetin treatment)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control
Number of subjects: 241
Study: 3340660

Group type: EXPERIMENTAL
Intervention: Maximal stabilization procedure
Number of subjects: 15

Group type: COMPARATOR
Intervention: Minimal stabilization procedure
Number of subjects: 15
Study: 31539628

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30807755

Group type: EXPERIMENTAL
Intervention: Matched limb training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mismatched limb training
Number of subjects: 20
Study: 28922340

Group type: EXPERIMENTAL
Intervention: Continuous non-invasive BP monitoring
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (intermittent BP monitoring only)
Number of subjects: 160
Study: 26169781

Group type: COMPARATOR
Intervention: Prenatal oral vitamin D3 supplementation (4200 IU/wk)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Prenatal oral vitamin D3 supplementation (16,800 IU/wk)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Prenatal oral vitamin D3 supplementation (28,000 IU/wk)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Postpartum oral vitamin D3 supplementation (28,000 IU/wk)
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Placebo in the prenatal period
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Placebo in the postpartum period
Number of subjects: 1300
Study: 23454404

Group type: EXPERIMENTAL
Intervention: 25 μg desmopressin orally disintegrating tablet once daily
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 21570355

Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV‐1 vaccine
Number of subjects: 801

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 801
Study: 20016978

Group type: EXPERIMENTAL
Intervention: Figures with 'holes'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Figures with 'no-holes'
Number of subjects: 0
Study: 16339157

Group type: EXPERIMENTAL
Intervention: Digoxin at SDC 0.5-0.9 ng/mL
Number of subjects: 5548

Group type: EXPERIMENTAL
Intervention: Digoxin at SDC >=1.0 ng/mL
Number of subjects: 5548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5548
Study: 15322438

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study: 11132321

Group type: EXPERIMENTAL
Intervention: Recombinant growth hormone (rGH) administered subcutaneously at a dose of 0.5 lU/kg per day for 28 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Recombinant growth hormone (rGH)
Number of subjects: 49
Study: 9358208

Group type: EXPERIMENTAL
Intervention: Myogard (test product)
Number of subjects: 22
Study: 8118901

Group type: EXPERIMENTAL
Intervention: Active motion and continuous passive motion (CPM) rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsurgical therapy
Number of subjects: 0
Study: 30659990

Group type: EXPERIMENTAL
Intervention: Endocuff Vision
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 200
Study: 29617704

Group type: EXPERIMENTAL
Intervention: Positive false feedback (active neurofeedback expectation)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Negative false feedback (placebo with false feedback)
Number of subjects: 46
Study: 28134676

Group type: EXPERIMENTAL
Intervention: Lateral decubitus position
Number of subjects: 82

Group type: COMPARATOR
Intervention: Traction table
Number of subjects: 82
Study: 26325557

Group type: EXPERIMENTAL
Intervention: Finerenone 7.5 mg/d
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Finerenone 10 mg/d
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Finerenone 15 mg/d
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Finerenone 20 mg/d
Number of subjects: 821

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821

Group type: COMPARATOR
Intervention: Finerenone and Placebo
Number of subjects: 821
Study: 22484413

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20mg, t.i.d.) for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21527115

Group type: EXPERIMENTAL
Intervention: Metformin + pioglitazone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Metformin + glimepiride
Number of subjects: 46
Study: 18958842

Group type: EXPERIMENTAL
Intervention: rosiglitazone (8 mg daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: glimepiride (3 mg daily)
Number of subjects: 12
Study: 16760682

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12663295

Group type: EXPERIMENTAL
Intervention: Oligofructose-supplemented cereal (0.55 g/15 g cereal)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Nonsupplemented cereal
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Cereal fortified with zinc (1 mg/15 g cereal)
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Cereal containing both zinc and prebiotics
Number of subjects: 631
Study: 11214033

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8633815

Group type: EXPERIMENTAL
Intervention: Nevirapine, zidovudine, and didanosine (triple-combination regimen)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Zidovudine and didanosine (double-combination regimen)
Number of subjects: 398
Study: 1814737

Group type: EXPERIMENTAL
Intervention: dipyridamole-beta-cyclodextrin complex (dip-beta-CD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: dipyridamole
Number of subjects: 12
Study: 6668457

Group type: EXPERIMENTAL
Intervention: Heme-iron supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31930222

Group type: EXPERIMENTAL
Intervention: DIVER‐100® (2 capsules/day for 10 days per month, for 3 months)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: DIVER‐100®
Number of subjects: 101
Study: 29554535

Group type: EXPERIMENTAL
Intervention: escitalopram (10 mg twice/day) + CBX (200 mg twice/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: escitalopram (10 mg twice/day) + placebo (twice/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Healthy control group (N = 35)
Number of subjects: 47
Study: 26727475

Group type: EXPERIMENTAL
Intervention: CPAP system plus heated humidifier and an integrated heated breathing tube
Number of subjects: 88

Group type: COMPARATOR
Intervention: CPAP system plus conventional heated humidifier
Number of subjects: 88
Study: 24560438

Group type: EXPERIMENTAL
Intervention: Memantine 40 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 22234683

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 100 mg twice daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 200 mg once daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Plain aspirin 100 mg once daily
Number of subjects: 41
Study: 19781072

Group type: EXPERIMENTAL
Intervention: Rhinovirus (RV) group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both RV and RSV groups
Number of subjects: 50
Study: 17471113

Group type: EXPERIMENTAL
Intervention: HSV-2 serologic testing
Number of subjects: 344

Group type: COMPARATOR
Intervention: HSV-2 negative or previously diagnosed participants
Number of subjects: 344
Study: 15209959

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 30 mg b.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fexofenadine (any dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Any fexofenadine doses
Number of subjects: 0
Study: 11260249

Group type: EXPERIMENTAL
Intervention: Doxepin cream (5%) applied 4 times daily for 3 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Basic ointment (control) applied 4 times daily for 3 days
Number of subjects: 11
Study: 10176088

Group type: EXPERIMENTAL
Intervention: Higher-intensity home-based exercise
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Higher-intensity class-based exercise
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lower-intensity home-based exercise
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Adherence change during the adoption phase
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Baseline self-efficacy
Number of subjects: 63
Study: 8047334

Group type: EXPERIMENTAL
Intervention: Spray application of 1% cyclopentolate hydrochloride
Number of subjects: 37

Group type: COMPARATOR
Intervention: Drop instillation of 1% cyclopentolate hydrochloride
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Spray application of cyclopentolate hydrochloride
Number of subjects: 37

Group type: COMPARATOR
Intervention: Drop instillation of cyclopentolate hydrochloride
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 37
Study: 2557203

Group type: EXPERIMENTAL
Intervention: Olive-oil-rich diet
Number of subjects: 124

Group type: COMPARATOR
Intervention: Carbohydrate-rich, high-fibre diet
Number of subjects: 124
Study: 31375390

Group type: EXPERIMENTAL
Intervention: VATS wedge resection
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: VATS segmentectomy
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: VATS lobectomy
Number of subjects: 424

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 424
Study: 30888330

Group type: EXPERIMENTAL
Intervention: tablet+messages
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: tablet only
Number of subjects: 1500

Group type: COMPARATOR
Intervention: no intervention (control)
Number of subjects: 1500
Study: 28718233

Group type: EXPERIMENTAL
Intervention: 10 mg of 0.5% hyperbaric bupivacaine (Group A)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 12 mg of 0.5% hyperbaric bupivacaine (Group B)
Number of subjects: 200
Study: 26033080

Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation Group (PNFG)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pilates Group (PG)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 63
Study: 23561946

Group type: COMPARATOR
Intervention: Doxepin (10 mg daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy with bright light therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21479287

Group type: EXPERIMENTAL
Intervention: Experimental 95% zirconia 5% alumina ceramic
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hard machined zirconia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Soft machined zirconia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 30
Study: 19549691

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg bid the day before and the day of the procedure plus saline i.v. 0.9% 1 ml/kg/h 12-24 h before and 24 h after the procedure)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo and saline at the same time intervals
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 200
Study: 16700815

Group type: EXPERIMENTAL
Intervention: New insoluble-matrix retropalpebral ophthalmic insert containing 5.38 mg phenylephrine and 0.28 mg tropicamide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Phenylephrine 10% and tropicamide 0.5% eyedrops
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both treatments (insert and eye drops)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: New insoluble-matrix retropalpebral ophthalmic insert
Number of subjects: 18
Study: 14668607

Group type: EXPERIMENTAL
Intervention: PEEP (0, 5, 10, and 15 cm H2O) in both supine and prone positions
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PEEP and prone position together
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PEEP in patients with diffuse infiltrates
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PEEP in patients with localized infiltrates
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lower inflection point
Number of subjects: 25
Study: 10960643

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 200 microg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Dinoprostone 0.5 mg every 6 hours (maximum four doses)
Number of subjects: 200
Study: 8985996

Group type: EXPERIMENTAL
Intervention: Solution A (Methenamine)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Solution B (blank solution)
Number of subjects: 16
Study: 1462902

Group type: EXPERIMENTAL
Intervention: Lidocaine (100 mg intravenous bolus followed by 300 mg intramuscular injection)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 3913425

Group type: EXPERIMENTAL
Intervention: 30 mg nicergoline (Sermion) daily for 180 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: 6 mg dihydroergotamine mesilate (DHETM) daily for 180 days
Number of subjects: 28
Study: 30838731

Group type: EXPERIMENTAL
Intervention: Green LED phototherapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Blue LED phototherapy
Number of subjects: 34
Study: 28973389

Group type: EXPERIMENTAL
Intervention: REALM‐R test
Number of subjects: 500
Study: 28378852

Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Monk fruit
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stevia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 10
Study: 24923987

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23435091

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 375
Study: 21272875

Group type: EXPERIMENTAL
Intervention: Single-balloon endoscopy (SBE)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Double-balloon endoscopy (DBE)
Number of subjects: 38
Study: 19709504

Group type: EXPERIMENTAL
Intervention: Active rTMS (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham treatment (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (active rTMS and sham)
Number of subjects: 20
Study: 16766000

Group type: EXPERIMENTAL
Intervention: Dynamic human face with associated human vocalizations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dynamic monkey face with species-appropriate vocalization
Number of subjects: 0

Group type: COMPARATOR
Intervention: House with opening front door and creaking door sound
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human face paired with non-human sound
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual ERPs at trial onset
Number of subjects: 0
Study: 15541179

Group type: EXPERIMENTAL
Intervention: Cuddling (nonpharmacological intervention)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Pain ratings (0-10 scale and 0-6 Faces Pain Scale)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Distress ratings (0-10)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Time to calm without intervention (seconds)
Number of subjects: 95
Study: 12774159

Group type: EXPERIMENTAL
Intervention: Magnesium infusion (1 mmol/kg)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 9512843

Group type: EXPERIMENTAL
Intervention: Prophylactic epidural blood patch (PEBP) recommended by 37% of centres; more common in US than Canadian centres.
Number of subjects: 137250

Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EBP) offered most commonly at or within 24 hours of diagnosis of post-dural puncture headache (PDPH).
Number of subjects: 137250

Group type: EXPERIMENTAL
Intervention: Unrestricted mobilisation advocated by 86% of centres following delivery.
Number of subjects: 137250

Group type: EXPERIMENTAL
Intervention: Resiting the catheter at another level was the most common initial response to dural puncture.
Number of subjects: 137250
Study: 8031017

Group type: EXPERIMENTAL
Intervention: Siemens Lithostar Plus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Storz Medical Modulith SL 10
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both apparatuses
Number of subjects: 0
Study: 2722372

Group type: EXPERIMENTAL
Intervention: Augmented water supply through handpumps and health education
Number of subjects: 623

Group type: COMPARATOR
Intervention: No project inputs (Control)
Number of subjects: 623